This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This new document builds off of the previously published BestPractices for Consumer Cardiovascular Technology Solutions in January 2022. Cardiovasculardisease is the leading cause of death globally, taking an estimated 695,000 lives in 2021 in the United States, about 1 in every 5 deaths, according to the CDC.
The new scientific statement, “Use of Artificial Intelligence in Improving Outcomes in Heart Disease,” comes amid intense attention on AI as a way to improve cardiovasculardisease prevention, detection, diagnosis and treatment.
Findings of a review of data from three clinical trials challenge current bestpractice for use of the drug for primary prevention of heart disease or stroke -- otherwise known as atherosclerotic cardiovasculardisease.
However, conversations are ongoing around bestpractices and standards of care regarding contrast management and treatment for those with higher risk factors, like compromised renal function. ACIST informs interventional decisions during peripheral, cardiovasculardisease and structural heart procedures.
This scientific statement outlines the current state of the art on the use of artificial intelligence algorithms and data science in the diagnosis, classification, and treatment of cardiovasculardisease.
This requires an interoperability framework that enables the deployment of platforms, sensors, devices, and software applications within diverse health systems, aiming to facilitate innovation in preventing and treating cardiovasculardisease.
Within the complex umbrella of cardiovasculardisease, CAD is a type of heart disease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart.
In its announcement about the workbook, ACC noted that cardiologists use digital devices and wearable technology to remotely monitor their patients for a variety of chronic cardiovasculardiseases, including heart failure, coronary artery disease, vascular disease and atrial fibrillation.
However, conversations are ongoing around bestpractices and standards of care regarding contrast management and treatment for those with higher risk factors, like compromised renal function. ACIST informs interventional decisions during peripheral, cardiovasculardisease and structural heart procedures.
In a room of 20 people, it’s likely that about 10 of them, or half, will presently have some form of cardiovasculardisease (CVD). CVD is among the most prevalent diseases in the U.S., and strokes and other CVDs are on the rise globally. Atrial fibrillation (AFib) cases have also surged, doubling from 28.3 million in 1990 to 56.7
Blood pressure guidelines serve as a beacon of bestpractice for the diagnosis and management of hypertension. Hypertension, Ahead of Print. The many cultural and societal differences in hypertension risk factors and management patterns across geographic regions support the need for geographically distinct international guidelines.
Cardiovascular Update for the Clinician: A Symposium by Valentin Fuster” will offer the latest advances in the treatment of cardiovasculardisease and ways to integrate them into daily practice. This includes a review of updated clinical guidelines and bestpractices.
These EHR reporting tools enable risk stratification, allowing clinicians to identify patients at high risk for cardiovasculardiseases through comprehensive data analysis. Clinicians can compare patient outcomes, treatments, and interventions with the broader cardiology population, enabling evidence-based decision-making.
The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovasculardisease ( CVD ) in National Health Service (NHS) clinical practice. Prevention is at the heart of what we do as GPs and risk assessment underpins that.
The forum has been created to facilitate the exchange and learning of bestpractices in research funding, identifying key shared research priority areas and impacting global policy in cardiovasculardisease.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content